Geoff Pardo joined Gilde Healthcare in 2011 as a Partner leading the U.S. investment activities in Boston/Cambridge, MA . He led the investments in Ablative Solutions, Inari Medical (NASDAQ: NARI), Axonics Modulation Technologies (NASDAQ: AXNX), CVRx, Vesper Medical, InovaLabs (acquired by ResMed), BionX (acquired by Ottobock) and Vapotherm (NYSE: VAPO) and represents Gilde as a member of the board of directors for each company.
Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience (sold to J&J) and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics.
Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activities in the medical device sector.
Geoff began his career in medical devices as a product manager with Synthes USA.
He has a B.A. with honors in History from Brown University and an M.B.A. from the Wharton School of Business. He is a US citizen based in Gilde Healthcare’s Cambridge, MA office.